Ovarian Cancer: Implications for the Pharmacist

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.

Ovarian cancer is the fifth most frequent cause of cancer death in women. It is imperative that pharmacists are aware of the therapeutic options for the management of ovarian cancer including the novel poly (ADP-ribose) polymerase inhibitors (PARP inhibitors). This session will cover the mechanism of action of the PARP inhibitors and the efficacy and safety parameters of the ovarian cancer treatment options available.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

  • Describe the etiology and pathophysiology of ovarian cancer.
  • Outline the efficacy and safety of treatment options for ovarian cancer.
  • Explain the mechanism of action of poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) available for ovarian cancer.
  • Explain how to evaluate the appropriate selection of therapy for specific ovarian cancer patients.

Faculty

Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington

Steering/Review Committee

Michael Heikkinen, PharmD; Jennifer Powers, PharmD; Marcy Snell, PharmD, CSP

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Jennifer Powers has served as a Consultant for Power-Pak CE. Michael Heikkinen, Megan May, and Marcy Snell have no relevant commercial and/or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 10-22-2018
Expiration Date: 10-22-2021

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-377-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 0.75 contact hour(0.075 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

This activity is self-funded by NASP.

 

Credit Information

Activity Number Credit Amount Accreditation Period
0221-9999-18-377-H01-P 0.75 Contact Hours October 22, 2018 - October 22, 2021